AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 JUL 11 - (NewsRx.com & NewsRx.net) --
by N.R. Saltmarsh, staff medical writer - The novel cytokine interleukin (IL)-18 can stimulate systemic antitumor effects in mice with renal cell carcinoma, say researchers working in Japan.
S. Hara and colleagues at Kobe University proposed that because IL-18 is a strong inducer of interferon gamma, has bioactivity similar to IL-12, and demonstrates antitumor effects, it might be useful as a cancer vaccine.
"Since IL-18 does not have a signal sequence, we constructed the gene, consisting of the signal sequences of interferon-beta and mature IL-18 complementary (c) DNA," reported Hara and team in the Journal of Urology.
The researchers used the overlap extension method to construct modified IL-18 cDNA, then transduced both modified and original IL-18 cDNA into the RenCa mouse renal cell carcinoma cell line to determine whether the cell line could induce systemic tumor immunity after secreting IL-18.
Although both the modified and original IL-18-transduced RenCa lines showed almost the same level of IL-18 messenger RNA expression, only RenCa cells transduced with the modified IL-18 gene secreted IL-18 into the culture supernatant and were completely rejected when transplanted into syngeneic mice, reported Hara and coworkers.
More important, mice injected with modified IL-18-transduced RenCa were ...